Current experimental therapy.
For successful experimental therapy of canine hematopoietic tumors, one must have a randomized homogeneous population of patients in reasonably good condition. Drug combinations should contain several agents, each with antitumor effect, acceptable toxicity, and of reasonable cost. Other modalities include biological response modifiers, radiation, differentiation-inducing agents, and marrow transplantation. Ways must be found to prevent drug resistance of tumor cells.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D004283:Dog Diseases / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D004285:Dogs; D004989:Ethics; D005818:Genetic Engineering / Q000662:veterinary; D006413:Hematopoietic System; D006979:Hyperthermia, Induced / Q000662:veterinary; D007167:Immunotherapy / Q000662:veterinary; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy / Q000662:veterinary*; D010956:Plasmapheresis / Q000662:veterinary
D000970:Antineoplastic Agents